Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
For women receiving breast RT who develop a severe skin reaction during treatment, what is your threshold for giving a treatment break?
When do you institute a treatment break for skin reaction for patients who receive breast radiation?
Answer from: Radiation Oncologist at Community Practice
I would for symptomatic grade 3 Reaction although in era of hypofractination it is very uncommon. Sometimes would do boost RT in the break period
Sign In
or
Register
to read more
3019
Related Questions
Given the new ASCO guidelines on SNB in early stage breast cancer, how does the omission of SNB in patients aged 50-70 impact your adjuvant radiation recommendations?
Is ultrahypofractionation appropriate for a B51 candidate receiving breast-only radiation?
Is stage I B/L breast, ER+ cancer a contraindication to breast radiation omission after breast conservation surgery?
Given the 10-year outcomes of UK FAST-Forward presented at ESTRO, how have you expanded the use of ultra-hypofractionation in your practice?
How would you manage an isolated nodal recurrence of breast cancer in a patient with a prior history of mantle-field radiation?
What is your preferred comprehensive nodal irradiation approach in non-metastatic breast cancer patients with underlying respiratory diseases or poor baseline respiratory function in light of the findings from the RadComp Trial?
When treating chestwall + RNI with VMAT, how much do you crop the PTV into lung as is done with the PTVeval in 3D contouring guides?
How do your PMRT recommendations change with ITCs after neoadjuvant chemotherapy if they had SLNB only versus ALND in light of B51?
Have the 10-year results from UK FAST-Forward presented at ESTRO 2025 impacted your practice with regard to patient selection?
Is re-excision of residual disease ever itself an indication for PMRT?